Vinh An Tran

Abstract The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity. However, substantial inter-person variability exists in both weight loss efficacy and the incidence of side effects1.

I have an aunt who is more than 70 years old and lives alone in the countryside. She used to spend all day, every day, alone with her two dogs and a cat. Recently she got a smartphone and started to learn to use the internet. She began calling me every week, asking the same questions, like "What are you doing?" and "Have you had lunch yet?" I happily answered her every time. But many of my cousins aren't so courteous.

The VGS Group, a preeminent corporation at the forefront of Vietnam's diverse golf ecosystem and the initial developer operator of the national golf handicap system - vHandicap, has announced a transition in ownership. Vo Duy Nghia will helm the group as the new Chairman and CEO. Nghia, a seasoned golfer with extensive experience in technology and media business management, has acquired the entire stake in VGS Group and is actively implementing plans for this new journey.